<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>183(5)</volume><submitter>Le Cleach L</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Acral lesions, mainly chilblains, are the most frequently reported cutaneous lesions associated with COVID-19. In more than 80% of patients tested, nasopharyngeal swabs were negative on reverse transcription polymerase chain reaction (RT-PCR) for SARS-CoV-2 when performed, and serology was generally not performed.&lt;h4>Methods&lt;/h4>A national survey was launched on 30 March 2020 by the French Society of Dermatology asking physicians to report cases of skin manifestations in patients with suspected or confirmed COVID-19 by using a standardized questionnaire. We report the results for acral manifestations.&lt;h4>Results&lt;/h4>We collected 311 cases of acral manifestations [58.5% women, median age 25.7 years (range 18-39)]. The most frequent clinical presentation (65%) was typical </pubmed_abstract><journal>The British journal of dermatology</journal><pagination>866-874</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7361395</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on polymerase chain reaction and serology testing.</pubmed_title><pmcid>PMC7361395</pmcid><pubmed_authors>Fourati S</pubmed_authors><pubmed_authors>Monfort JB</pubmed_authors><pubmed_authors>Boulard C</pubmed_authors><pubmed_authors>Levy Roy A</pubmed_authors><pubmed_authors>Wolkenstein P</pubmed_authors><pubmed_authors>Le Cleach L</pubmed_authors><pubmed_authors>Lesort C</pubmed_authors><pubmed_authors>Colin A</pubmed_authors><pubmed_authors>Samimi M</pubmed_authors><pubmed_authors>Beylot-Barry M</pubmed_authors><pubmed_authors>Dousset L</pubmed_authors><pubmed_authors>Tardieu M</pubmed_authors><pubmed_authors>Assier H</pubmed_authors><pubmed_authors>Marco-Bonnet J</pubmed_authors><pubmed_authors>Lombart F</pubmed_authors><pubmed_authors>French Society of Dermatology</pubmed_authors><pubmed_authors>Cambon L</pubmed_authors><pubmed_authors>Sbidian E</pubmed_authors><pubmed_authors>Kostrzewa E</pubmed_authors><pubmed_authors>Barbarot S</pubmed_authors><pubmed_authors>Bourseau Quetier C</pubmed_authors><pubmed_authors>Cazanave C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on polymerase chain reaction and serology testing.</name><description>&lt;h4>Background&lt;/h4>Acral lesions, mainly chilblains, are the most frequently reported cutaneous lesions associated with COVID-19. In more than 80% of patients tested, nasopharyngeal swabs were negative on reverse transcription polymerase chain reaction (RT-PCR) for SARS-CoV-2 when performed, and serology was generally not performed.&lt;h4>Methods&lt;/h4>A national survey was launched on 30 March 2020 by the French Society of Dermatology asking physicians to report cases of skin manifestations in patients with suspected or confirmed COVID-19 by using a standardized questionnaire. We report the results for acral manifestations.&lt;h4>Results&lt;/h4>We collected 311 cases of acral manifestations [58.5% women, median age 25.7 years (range 18-39)]. The most frequent clinical presentation (65%) was typical </description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Nov</publication><modification>2025-05-29T22:25:46.354Z</modification><creation>2022-07-19T08:25:51.026Z</creation></dates><accession>S-EPMC7361395</accession><cross_references><pubmed>32628270</pubmed><doi>10.1111/bjd.19377</doi></cross_references></HashMap>